U.S. Approves Oncology Drugs Approved More Quickly Than Other Drugs

A recent study indicates while American regulators approve cancer treatments more rapidly, the opposite is true in Europe. Approval times for new oncology drugs in the United States during the last decade were shorter than approval times for non-oncology products, while the reverse was the case in the European Union, according to a study recently completed by the Tufts Center for the Study of Drug Development.

FDA Announces Changes in Drug Center’s Oncology Office

Review divisions to be aligned by expertise, disease-specific areas

No votes yet
Syndicate content